EGFR and non-small cell lung carcinoma: In this phase I trial (NCT0199998), Dasatinib revealed high tolerance in cancer patients who progressed after EGFR inhibitors and feasibility in advanced NSCLC at biologically active dosages in conjunction with afatinib.